Personalized medicine

Induced Pluripotent Stem Cell (iPSC) Industry Market Size, Trends, and Forecast Report - ResearchAndMarkets.com

Retrieved on: 
星期二, 五月 7, 2024
Health, Stem Cells, OA, Cellular Dynamics International, University, Microsoft Exchange Server, Cell, CRISPR, Safety, Drug development, Osteoarthritis, World Games, MSC, Partnership, Research, CLI, B cell, Application, Disease, Human, Therapy, Patient, COVID-19, Tissue engineering, Graft-versus-host disease, IPSC, Medicine, Kyoto University, 3D bioprinting, Macular degeneration, Regenerative medicine, CDI, Clinical trial, Toxicology, Drug discovery, Personalized medicine, Merck, Thermo Fisher Scientific, Pharmaceutical industry

The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Since the discovery of induced pluripotent stem cell (iPSC) technology in 2006, significant progress has been made in stem cell biology and regenerative medicine.
  • Today, methods of commercializing induced pluripotent stem cells (iPSCs) include:
    Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.
  • This global strategic report reveals all major market competitors worldwide, including their core technologies, strategic partnerships, and products under development.

Concert Announces Clinical Advisory Board, New Medical Policies

Retrieved on: 
星期三, 五月 1, 2024
Cepheid variable, FDA, Biochemistry, Doctor of Philosophy, Cardiovascular disease, Vanderbilt University Medical Center, Associate, Palmetto, Prevalence, Concert, Global health, Congress, COVID, CRS, Food, Princeton University, Yale University, DRS, Duke University, Microbiology, Infection, Assistant, Molecular biology, Humana, Staphylococcus, Congressional Research Service, MD–PhD, Health, Library, Neuroscience, Research, Personalized medicine, Emory School, Public policy, Immunology, Medicine, Health policy, Maryland School, Government, Division, Rice University, University, Goucher College, Public health, MD, Duke, Staphylococcus aureus, Wake Forest University, Patient, Internal medicine

NASHVILLE, Tenn., May 1, 2024 /PRNewswire/ -- As part of its commitment to provide transparent, evidence-based medical policy and enable accurate reimbursement for a broader set of diagnostic services, Concert today announced the establishment of an advisory board of experts in clinical laboratory medicine and the release of policies for an expanded scope of routine and advanced laboratory testing.

Key Points: 
  • The newly formed board will advise Concert on its clinical laboratory content.
  • "Concert is working to align payers, providers, and labs to enable patient access to evidence-based testing," said Dr. Girish Putcha.
  • Following are brief bios on each member of the new clinical advisory board, in alphabetical order by last name.
  • Recent roles include Director of Laboratory Science at Palmetto's MolDX program, Chief Medical Officer and Clinical Laboratory Director of Freenome, and Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) member.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
星期二, 四月 30, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, Research, VCF, Artificial intelligence, Dysbiosis, Personalized medicine, Multiomics, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

DUBAI, UAE, April 30, 2024 /PRNewswire/ -- BioAro, a pioneer in genomic research and technology, is set to officially launch PanOmiQ, a revolutionary software that will redefine the landscape of genomic analysis globally by providing real-time insights into the complexities of the human genome. With unparalleled speed, precision, and versatility, it promises to transform healthcare worldwide. The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

Global Clinical Trials Market Analysis, Size, and Forecasts 2023 and 2024-2030 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, Sanofi, and Medpace - ResearchAndMarkets.com

Retrieved on: 
星期二, 四月 23, 2024
Health, Clinical Trials, USD, FDA, Phase, Cancer, Pain management, SARS-CoV-2, Food, Viral, Intervention, Personalized medicine, Blockchain, Machine learning, Diabetes, National Cancer Institute, Research, Vaccine, ChromeOS, Therapy, Incidence, Patient, NCI, Clinical trial, Expanded access, Prevalence, Pharmaceutical industry

The global clinical trials market is split into phases: Phase 1, Phase 2, Phase 3, and Phase 4.

Key Points: 
  • The global clinical trials market is split into phases: Phase 1, Phase 2, Phase 3, and Phase 4.
  • By indication, the global clinical trials market is categorized into Autoimmune/Inflammation, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, and Others.
  • By study material, the global clinical trials market is fragmented into Interventional, Observational, and Expanded Access.
  • The requirement for clinical trials to improve diagnostic tests and vaccines for viral illnesses such as SARS-CoV-2 has exponentially augmented the demand for clinical trials.

Global Precision Medicine Software Markets, 2023-2024 and 2033: Burgeoning Opportunities with Enhancements in the Field Using Integrated and Automated Solutions & Utilizing Artificial Intelligence - ResearchAndMarkets.com

Retrieved on: 
星期四, 四月 18, 2024
Health, Technology, Genetics, Other Health, Other Science, Software, Science, HIPAA, Cancer, GDPR, Personalized medicine, Region, Machine learning, Research, Artificial intelligence, Information technology, Environment, Patient, Patient satisfaction, Medicine, Biotechnology, Organization, Growth, Medical device

The precision medicine software market has witnessed substantial growth in recent years, driven by the convergence of healthcare and cutting-edge technologies.

Key Points: 
  • The precision medicine software market has witnessed substantial growth in recent years, driven by the convergence of healthcare and cutting-edge technologies.
  • The industrial impact on the precision medicine software market has been profound, with various sectors contributing to the growth and advancement of this specialized field.
  • Competitive Strategy: The global precision medicine software market is a highly fragmented market, with many smaller and private companies constantly entering the market.
  • Key players in the precision medicine software market analyzed and profiled in the study involve established players that offer various kinds of products.

Global Research Antibodies & Reagents Market Outlook & Forecasts, 2023 and 2024-2029: Growing Demand for Precision Medicine, Rising Focus on Biomarker Discovery, & Rise in Proteomics and Genomics - ResearchAndMarkets.com

Retrieved on: 
星期五, 四月 12, 2024
Health, Stem Cells, Genetics, Research, Science, Biotechnology, USD, Immunoprecipitation, Antibody, Cancer, Genomics, Protein, Cell biology, ELISA, Heart, Personalized medicine, Proteomics, Immunohistochemistry, Biomedical Research, Biomarker, Growth, University, Disease, ChromeOS, Bio-Rad Laboratories, Therapy, Northern blot, Patient, Chemistry, Medicine, Diagnosis, Antigen, Gene expression, Genome, Elisa's, Drug development, Biology, Molecular biology, Drug discovery, Thermo Fisher Scientific, Gene, Flow cytometry, Fine chemical

North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.

Key Points: 
  • North America holds the most prominent share of the global research antibodies & reagents market, accounting for over 39% in 2023.
  • This paradigm shift presents a substantial opportunity for the research antibodies & reagents market, an essential component of precision medicine research.
  • The reagents product type accounted for the most significant global research antibodies & reagents market share in 2023.
  • The academics & research institutes and research labs end-user segment dominated the global research antibodies & reagents market share in 2023.

BioAro Announces a Medical and Computing Breakthrough by Launching the 'World's Fastest' Real-Time Genomic Software 'PanOmiQ'

Retrieved on: 
星期四, 四月 25, 2024
Irritable bowel syndrome, University, Transcriptome, Protein, AI, Metagenomics, Professor, Data format, Dubai World Trade Centre, AB, VCF, Research, Dysbiosis, Personalized medicine, Multiomics, Intelligence, DNA, Genome, Whole genome sequencing, Health, Biomarker, University of Patras, Genomics, Medicine, Quality of life, Longevity, IBS, Medical device

The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.

Key Points: 
  • The Global launch of PanOmiQ software will take place during the Precision Medicine Expo on May 9th, 2024, at Dubai World Trade Center, UAE.
  • As the culmination of years of research and development, PanOmiQ stands as the world's fastest genomic analysis software to date.
  • "Turnaround time in genomic analysis is critical, and this is where PanOmiQ comes in with its unmatched speed and accuracy.
  • Please join us at the Precision Medicine Expo on May 9th, 2024, at the Dubai World Trade Centre, where BioAro will introduce PanOmiQ's groundbreaking capabilities.

BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

Retrieved on: 
星期二, 四月 9, 2024
Organization, Conference, Drug discovery, COVID-19, Patient, Research, Artificial intelligence, Classification, Personalized medicine, Medicine, Quantum, Bullfrog, Machine learning, CSO

The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.

Key Points: 
  • The presentation, titled "Quantum Assisted AI/ML for Precision Medicine," is scheduled for 1 pm ET.
  • Chittenden's presentation will explain how quantum methods have been used to decipher complex disease patterns, including analysis of multi-omics cancer data and classification of severe COVID-19 patients.
  • "The research I will highlight during my presentation is a testament to the synergies between quantum computing and machine learning, offering novel solutions to longstanding challenges in biomedical sciences."
  • The Quantum Computing Symposium is a premier event for professionals in the pharmaceutical industry, highlighting the revolutionary role of quantum technologies across various sectors, including drug discovery and supply chain management.

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Retrieved on: 
星期五, 四月 5, 2024
Head, Algorithm, Immunotherapy, University, Neoplasm, PM, Vaccine, Analysis, Navigation, Mutation, Thermo Fisher Scientific, Cancer, Unprecedented, Glioblastoma, Result, Risk, Research, Tumor microenvironment, Antibody, Security (finance), Personalized medicine, PST, Proteomics, AACR, Pancreatic cancer, Ultrahigh, Conversation, Annual general meeting, AQUA, Lung cancer, University of Queensland, MIT, Titan Mare Explorer, Medical imaging

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.

Key Points: 
  • MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.
  • Industry-leading capabilities of the company’s spatial biology platforms will be presented during Akoya’s Spotlight Theater, titled “Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale” on Monday, April 8 at 3 PM (PST).
  • Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform.
  • PhenoImager HT 2.0: Features targeted PhenoCode Signature Panels and onboard spectral unmixing, simplifying biomarker development and validation workflows for large scale studies.

American Oncology Network Announces Attendance and Participation at Leading Community Oncology Conference

Retrieved on: 
星期四, 三月 28, 2024
Community, AON, CSSBB, Growth, Doctor of Pharmacy, Health, Partnership, Education, Patient, Knowledge, Cancer, COA, Hope, Matter, Personalized medicine, Community Oncology Alliance, MD, Privacy, Competition, MBA, Confidentiality, Pharmacy, Physician, Medicine, Pharmaceutical industry

FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.

Key Points: 
  • FORT MYERS, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC) announced its attendance and panel participation at the annual Community Oncology Alliance (COA) conference from April 4 to April 5 in Orlando, Florida, to further its mission of closing the cancer care gap and ensuring the viability of community oncology.
  • Since its inception, AON has provided administrative support and access to critical offerings such as the in-house pharmacy and laboratory services to independent oncology medical practices.
  • The conference brings together today’s healthcare and community oncology leaders for two days of education and networking.
  • We understand the future of healthcare is a collective effort, and the conference provides a platform to foster unity and the exchange of information.